Bancel: Moderna prints 34 cancer mutations into individualized vaccines in 30 days
Stéphane Bancel · Inside Moderna’s Biggest mRNA Test Since COVID · Sep 2, 2026 · at 14:08
Moderna CEO Stéphane Bancel describes Moderna's process for sequencing tumor mutations and manufacturing individualized mRNA cancer vaccines.
0:00 / 0:12exact quote · 12.1s
▶ Watch the full episode on YouTube → 720p mp4 · rendered on demand · StarZero watermark
“We select the 34 that we believe are the most relevant, and we stitch them together into one big mRNA molecule, which we make in thirty-ish days for you, that is injected then in a hospital intramuscularly.”
quote is from the automated transcript, cleaned for reading: filler sounds and stutters are removed, nothing is rephrased. names can be misheard (the analysis reads context, assessments check outside sources). how →
More from Stéphane Bancel
Bancel: Moderna's mRNA shot is the first cancer vaccine that works
“Here it's the first time there is a cancer vaccine working. The field, as you know, has been doing that for 20 plus years. I think more than a thousand clinical trials that have all failed.”
Bancel: Moderna's mRNA vaccine is first melanoma agent outperforming Keytruda alone
“It's the first time that there is an agent In melanoma that is better than Ketudra alone.”
Bancel: Moderna and Merck Phase 3 individualized mRNA cancer trial is positive
“So indeed last week now we shared the news with our colleagues at Merck that after working 10 years on the individualized treatment against cancer using mRNA technology, that the phase three was positive.”
Bancel: Moderna Phase 3 trial met primary and secondary endpoints at first interim analysis
“What we announced last week is that we met the primary End point of a study, which was recurrence-free survival, i.e. People having the cancer back or dying, that we met, and then to our own surprise, because this was the first interim analysis. This is not th…”
Bancel: Moderna's Massachusetts factory is ready for individualized manufacturing at scale
“The factory is ready in Massachusetts, but we have figured out how to make and scale a product for every human being at the time.”
Bancel: Moderna trial data showed 90% of cancer antigens differ across patients
“And what we showed at ASCO and we published from a phase two study, but we believe it's the same thing in the phase three, because it's mechanistic, is that around 99 zero percent of the antigen are different patient to patient.”